CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing more effective therapeutic antibodies for cancer and autoimmune diseases. By utilizing advanced techniques to analyze immune responses, it aims to enhance patient stratification and improve treatment outcomes for conditions like melanoma and rheumatoid arthritis.
Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$.
In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma.
However, for most antibody therapies, only a subset of patients benefit from treatment.
Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for…
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Siena
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Switzerland, Otelfingen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Netherlands, Amsterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Jena
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
